NSGO Publication List Peer reviewed publications 22.09.2014

NSGO Publication List
Peer reviewed publications
22.09.2014
2014
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
du Bois A1, Floquet A2, Kim JW 2, Rau J2, Del Campo JM2, Friedlander M2, Pignata S2, Fujiwara K2,
Vergote I2, Colombo N2, Mirza MR2, Monk BJ2, Kimmig R2, Ray-Coquard I2, Zang R2, Diaz-Padilla I2,
Baumann KH2, Mouret-Reynier MA2, Kim JH2, Kurzeder C2, Lesoin A2, Vasey P2, Marth C2, Canzler U2,
Scambia G2, Shimada M2, Calvert P2, Pujade-Lauraine E2, Kim BG2, Herzog TJ2, Mitrica I2, SchadeBrittinger C2, Wang Q2, Crescenzo R2, Harter P2
J Clin Oncol. 2014 Sep 15. pii: JCO.2014.55.7348.
Shall we settle for low-level evidence?
Mirza MR
J Gynecol Oncol. 2014 Jul;25(3):162-163. English.
Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating
Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer.
Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz
JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E.
J Clin Oncol. 2014 Mar 31. [Epub ahead of print] PMID: 24687829 [PubMed - as supplied by
publisher]
Related citations
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer:
The AURELIA Open-Label Randomized Phase III Trial.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I,
Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, RayCoquard I.
J Clin Oncol. 2014 Mar 17. [Epub ahead of print] PMID: 24637997 [PubMed - as supplied by
publisher]
Related citations
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the
Nordic Society of Gynecologic Oncology (NSGO).
Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote
I, Rosenberg P, Boman K, Nordstrøm B.
BMC Cancer. 2014 Feb 5;14:68. doi: 10.1186/1471-2407-14-68.PMID: 24498853 [PubMed - in
process] Free PMC Article
Related citations
1
2013
Gynecologic Cancer InterGroup (GCIG) endometrial cancer clinical trials planning meeting: taking
endometrial cancer trials into the translational era.
Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson
R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G; GCIG Endometrial Cancer Clinical Trials
Planning Meeting.
Int J Gynecol Cancer. 2013 Oct;23(8):1528-34. doi: 10.1097/IGC.0b013e3182a26edb.
PMID: 24257568 [PubMed - in process]
Related citations
Roadmap for the European Network of Gynaecological Trial groups (ENGOT) Trials.
Vergote I, Elser G, Votan B, Farrelly L, De Roover J, Bryce J, du Bois A; member trial groups of the
European Network of Gynaecological Trial groups (ENGOT).
Int J Gynecol Cancer. 2013 Sep;23(7):1339-43. doi: 10.1097/IGC.0b013e31829b87da.
PMID: 23970159 [PubMed - indexed for MEDLINE]
Related citations
The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian
cancer: data from CALYPSO trial (a GINECO-GCIG study).
You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G,
Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A.
Gynecol Oncol. 2013 Aug;130(2):289-94. doi: 10.1016/j.ygyno.2013.05.013. Epub 2013 May 18
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent
ovarian cancer.
Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, SkeieJensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine
E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M.
Ann Oncol. 2013 Apr;24(4):937-43. doi: 10.1093/annonc/mds538. Epub 2012 Oct 26.
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life
outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised
trial.
Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A,
Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM,
Oza A, Perren T.
Lancet Oncol. 2013 Mar;14(3):236-43. doi: 10.1016/S1470-2045(12)70567-3. Epub 2013 Jan 18
2012
First line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin
(TEC vs. TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.
K. Lindemann1, R.D. Christensen2, I. Vergote3, G.Stuart4, M.A. Izquierdo5, J Kern1, H.
Havsteen6, E. Eisenhauer7, M. Ridderheim8, A.B. Lopez9, H. Hirte10, E. Aavall-Lundquvist11, E.
Vrdoljak12, J. Green13 and G.B. Kristensen1,14
Ann Oncol. 2012 Oct;23(10):2613-9. Epub 2012 Apr 26.
http://www.ncbi.nlm.nih.gov/pubmed/?term=22999502
2
Cancer of the corpus uteri.
Amant F, Mirza MR, Creutzberg CL.
Int J Gynaecol Obstet. 2012 Oct;119 Suppl 2:S110-7. doi: 10.1016/S0020-7292(12)60024-1. No
abstract available.
PMID: 22999502 [PubMed - indexed for MEDLINE]
Related citations
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and
carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo
MC, Fossati R, Gebski V, Lauraine EP.
Br J Cancer. 2012 Aug 7;107(4):588-91. doi: 10.1038/bjc.2012.307. Epub 2012 Jul 26
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially
platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase
III trial.
Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E,
Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S.
Annals of Oncology 23: 1185–1189, 2012 May
CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the
GCIG CALYPSO trial.
Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Mäenpää J, Chalchal H, Fitzharris B,
Volgger B, Vergote I, Pisano C, Ferrero A, Pujade-Lauraine E.
Br J Cancer. 2012 Feb 14;106(4):633-7. doi: 10.1038/bjc.2011.593. Epub 2012 Jan 12
Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the
CALYPSO trial
Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, Wolfram G, Reed N, Pignata S,
Ferrero A, Brown C, Eisenhauer E, Pujade-Lauraine E.
Ann Oncol. 2012 Jan 30. [Epub ahead of print]
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale
P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S,
Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza
AM; ICON7 Investigators.
N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. Erratum in: N Engl J
Med. 2012 Jan 19;366(3):284.
PMID: 22204725 [PubMed - indexed for MEDLINE] Free Article
Related citations
3
2011
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus
carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO
sub-study.
Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E,
Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E; on behalf of Gynecologic
Cancer Intergroup.
Ann Oncol. 2011 Nov;22(11):2417-2423. Epub 2011 Mar 14.
Impact of ABCB1 Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92
Women with Ovarian Cancer.
Bergmann TK, Brasch-Andersen C, Gréen H, Mirza MR, Skougaard K, Wihl J, Keldsen N, Damkier
P, Peterson C, Vach W, Brøsen K.
Basic Clin Pharmacol Toxicol. 2011 Sep 28. doi: 10.1111/j.1742-7843.2011.00802.x. [Epub ahead
of print] PMID: 21955855 [PubMed - as supplied by publisher]
Related citations
Prognostic nomogram to predict progression-free survival in patients with platinumsensitive recurrent ovarian cancer.
Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges
A, Bourgeois H, Högberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H,
Gebski V, Pfisterer J, Pujade-Lauraine E, Friedlander M
Br J Cancer. 2011 Oct 11;105(8):1144-50. doi: 10.1038/bjc.2011.364. Epub 2011 Sep 13.
Early decline in cancer antigen 125 as a surrogate for progression-free survival in
recurrent ovarian cancer
Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello
N, Schmalfeldt B, Delva R, Mirza MR, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes RJ.
J Natl Cancer Inst. 2011 Sep 7;103(17):1338-42.
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to
carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer
trial.
Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, Vaughan M, ReinthallerA,
Vergote I, Ferrandina G, Dell'Anna T, Huober J, Pujade-Lauraine E. Gynecol Oncol. 2011
Aug;122(2):226-32. Epub 2011 May 14.
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian
cancer study.
Herzog TJ, Vermorken JB, Pujade-Lauraine E, Provencher DM, Jagiello-Gruszfeld A, Kong B,
Boman K, Park YC, Parekh T, Lebedinsky C, Gómez J, Monk BJ.
Gynecol Oncol. 2011 Aug;122(2):350-5. Epub 2011 May 5.
Subspecialist training in surgical gynecologic oncology in the Nordic countries.
Antonsen SL, Avall-Lundqvist E, Salvesen HB, Auranen A, Salvarsdottir A, Høgdall C;
4
Nordic Society of Gynaecological Oncology.
Acta Obstet Gynecol Scand. 2011 Aug;90(8):917-20.
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in
recurrent ovarian cancer.
Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J,
Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M.
Br J Cancer. 2011 Jul 26;105(3):360-5.
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in
patients with ovarian cancer.
Bergmann TK, Gréen H, Brasch-Andersen C, Mirza MR, Herrstedt J, Hølund B, du Bois A, Damkier
P, Vach W, Brosen K, Peterson C.Eur J Clin Pharmacol. 2011 Jul;67(7):693-700. doi:
10.1007/s00228-011-1007-6. Epub 2011 Feb 16.
PMID: 21327421 [PubMed - indexed for MEDLINE]
Related citations
Clinical trials in recurrent ovarian cancer.
Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S,
Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R,
Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A,
Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup.
Int J Gynecol Cancer. 2011 May;21(4):771-5.
First-Line Therapy in Ovarian Cancer Trials.
Thigpen T, Dubois A, McAlpine J, Disaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R,
Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D,
Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC; on behalf of the
Gynecologic Cancer InterGroup.
Int J Gynecol Cancer. 2011 May;21(4):756-762.
Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic
study in 93 patients with ovarian cancer.
Bergmann TK, Brasch-Andersen C, Gréen H, Mirza M, Pedersen RS, Nielsen F, Skougaard K, Wihl
J, Keldsen N, Damkier P, Friberg LE, Peterson C, Vach W, Karlsson MO, Brosen K.
Pharmacogenomics J. 2011 Apr;11(2):113-20. doi: 10.1038/tpj.2010.19. Epub 2010 Apr 6.
PMID: 20368717 [PubMed - indexed for MEDLINE]
Related citations
Definitions for Response and Progression in Ovarian Cancer Clinical Trials IncorporatingRECIST
1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG).
Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A,
Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A,
Vermorken J.
Int J Gynecol Cancer. 2011 Feb;21(2):419-423
5
2010
The value of gynecologic cancer follow-up: evidence-based ignorance?
Lajer H, Jensen MB, Kilsmark J, Albæk J, Svane D, Mirza MR, Geertsen PF, Reerman D, Hansen
K, Milter MC, Mogensen O.
Int J Gynecol Cancer. 2010 Nov;20(8):1307-20. doi: 10.1111/IGC.0b013e3181f3bee0. Review.
PMID: 21051970 [PubMed - indexed for MEDLINE]
Related citations
A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using
gemcitabine and pegylated liposomal doxorubicin.
Mirza MR, Lund B, Lindegaard JC, Keldsen N, Mellemgaard A, Christensen RD, Bertelsen K.
Gynecol Oncol. 2010 Oct;119(1):26-31. doi: 10.1016/j.ygyno.2010.06.022. Epub 2010 Jul 17.
PMID: 20638711 [PubMed - indexed for MEDLINE]
Related citations
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-Results from two
randomised studies.
Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S,
Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G,
Clarke J, Sawicki T, Zola P, Kristensen G.
Eur J Cancer. 2010 Sep;46(13):2422-31
Addition of gemcitabine as third drug to carboplatin-paclitaxel in firstline treatment of epithelial
ovarian cancer. A prospectively randomized Gynecologic Cancer Intergroup (GCIG) Intergroup
trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group
(AGO-OVAR), the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens
(GINECO), and the Nordic Society of Gynecologic Oncology (NSGO).
Andreas du Bois, Jørn Herrstedt, Anne-Claire Hardy-Bessard, Hans-Helge Müller, Philipp Harter,
Gunnar Kristensen, Florence Joly, Jens Huober, Elisabeth Åvall-Lundqvist, Béatrice Weber,
Christian Kurzeder, Svetislav Jelic, Eric Pujade-Lauraine, Alexander Burges, Jacobus Pfisterer,
Martina Gropp, Anne Staehle, Pauline Wimberger, Christian Jackisch, Barbara Schmalfeldt, AntjeKristina Belau, Sibylle Loibl, Kerstin Wollschlaeger, Jalid Sehouli.
J Clin Oncol. 2010 Sep 20;28(27):4162-9
Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin for Patients
with Platinum-Sensitive Ovarian Cancer in Late Relapse
Eric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, Val Gebski, Mark Heywood, Paul
Vasey, Birgit Volgger, Ignace Vergote, Sandro Pignata, Annamaria Ferrero, Jalid Sehouli, Alain
Lortholary, Gunnar Kristensen, Christian Jackisch,
Florence Joly-Lobbedez, Chris Brown, Nathalie Le Fur, and Andreas du Bois
J Clin Oncol 28:3323-3329, 2010 July 10
European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials
Between Academic Groups and Pharmaceutical Companies
Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J,
6
Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A,
Tulunay G, van der Zee AG, du Bois A; European Network of Gynaecological Oncological Trial
Groups
Int J Gynecol Cancer 2010 April 20: 476-478
2009
Practice patterns of radiotherapy in endometrial cancer among member groups of the
Gynecologic Cancer Intergroup (GCIG)
W. Small, A. Du Bois, S. Bhatnagar, N. Reed, S. Pignata, R. Pötter, D. M. Randall, M. R. Mirza, E.
L. Trimble, K. Gaffney.
Int. J. Gynecol Cancer, 2009 April; 19: 395-399.
Intravaginal brachytherapy in FIGO Stage I low-risk endometrial cancer – a controlled randomized
study.Sorbe B, Nordström B, Mäenpää J, Kuhelj J, Kuhelj D, Okkan S, Delalouye J-F, Frankendal
B: Int J Gynecol Cancer 19: 873-878, 2009 July 19.
Endometrial cancer state of the science meeting
Kitchener HC, Trimble EL; Endometrial Cancer Working Group of the Gynecologic Cancer
Intergroup.
Int J Gynecol Cancer. 2009 Jan-Feb;19(1):134-40
Patterns of care for radiotherapy in vulvar cancer: A Gynecologic Cancer Intergroup
(GCIG) study.
D. K. Gaffney, A. Du Bois, K. Narayan, N. Reed, T. Toita, S. Pignata, P. Blake, L. Portelance, A.
Sadoyze, R. Pötter, A. Colombo, M. Randall, M. R. Mirza, E. L. Trimble.
Int. J. Gynecol Cancer, 2009 Jan; 19: 163-7.
2007
Clinical trials in gynecological cancer.
Trimble EL, Davis J, Disaia P, Fujiwara K, Gaffney D, Kristensen G, Ledermann J, Pfisterer J,
Quinn M, Reed N, Schoenfeldt M, Thigpen JT; Gynecologic Cancer Intergroup.
Int J Gynecol Cancer. 2007 May-Jun;17(3):547-56
Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic
Cancer Intergroup (GCIG).
D. K. Gaffney, A. Du Bois, K. Narayan, N. Reed, T. Toita, S. Pignata, P. Blake, L. Portelance, A.
Sadoyze, R. Pötter, A. Colombo, M. Randall, M. R. Mirza, E. L. Trimble.
Int. J. of Radiation OncologyBiologyPhysics, 2007 June 1; 68: 485-490
2006
Comparison of CA-125 and standard definitions of progression of ovarian cancer in the
7
intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.
Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart J, Bertelsen K,
Stuart G, Cassidy J, Eisenhauer E.
J Clin Oncol. 2006 Jan 1;24(1):45-51
2005
Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pre-treated with platinumtaxane: Results from a multicenter Phase I/II study.
Gronlund B, Engelholm SA, Horvath G, Mäenpää J, Ridderheim M.
Cancer 103: 1388-1396, 2005 april.
Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective
multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG
Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard
TC. Bois A, Sehouli J, Lund B, Joly F, Huober J, Jensen TS, Levy E, Heilmann V, Boman K, HardyBessard AC, Burges A, Mäenpää J, et al..
Int J Gynecol Cancer 15: Suppl 3: 224-225, 2005.
First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB-IV with paclitaxel/carboplatin
with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO,
EORTC GCG, and NCIC CTG. Results on progression-free survival.
Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Baekelandt M, Lopez AB, Hirte H,
Aavall-Lundqvist E, Lorenz E, Cerar O
Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:221.
Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens.
Thigpen T, Stuart G, du Bois A, Friedlander M, Fujiwara K, Guastalla JP, Kaye S, Kitchener H,
Kristensen G, Mannel R, Meier W, Miller B, Poveda A, Provencher D, Stehman F, Vergote I.
Ann Oncol. 2005 Oct;16 Suppl 8:viii13-viii19
2004 consensus statements on the management of ovarian cancer: final document of the
3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference
(GCIG OCCC 2004).
duBois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M,
Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP,
Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP,
Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade- Lauraine E,
Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I,
Verheijen R, Wagner U; Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO;
GINECO; GOG; JGOG; MRC/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS;
Organizational team of the two prior International OCCC.
Ann Oncol. 2005;16 Suppl 8:viii7-viii12.
3rd International Ovarian Cancer Consensus Conference: outstanding issues for future
consideration
Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A,
Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye
S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J,
8
Poveda A, Provencher D, Pujade-Lauraine E, Quinn M, Randall M, Rochon J, Rustin G, Sagae S,
Stehman F, Trimble E, Thigpen T, Vasey P, Vergote I, Verheijen R, Vermorken J, Wagner U; NCICCTG; NSGO; AGO-OVAR; GOG; ANZGOG; EORTC; GEICO; JGOG; GINECO; MRC/NCRI;
SGCTG; RTOG; NCI-US.
Ann Oncol. 2005;16 Suppl 8:viii36-viii38.
History, scope and methodology of the 3rd International Consensus Workshop on
Ovarian Cancer 2004.
Quinn M, Avall-Lundqvist E, du Bois A, Vermorken J, Parmar M, Pfisterer J, Stuart G,
Thigpen T, Neijt J.
Ann Oncol. 2005;16 Suppl 8:viii5-viii6.
The Gynecologic Cancer Intergroup (GCIG): history and current status.
Vermorken JB, Avall-Lundqvist E, Pfisterer J, Bacon M; GCIG; AGO-OVAR; ANZGOG; EORTCGCC; GEICO; GINECO; GOG; JGOG; MRC; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG.
Ann Oncol. 2005;16 Suppl 8:viii39-viii42
Integration of new or experimental treatment options and new approaches to clinical trials.
Quinn M, Pfisterer J, Avall-Lundqvist E, Bookman M, Bowtell D, Casado A, Cervantes A,
Grenman S, Harper P, Oza A, Pecorelli S, Pujade-Lauraine E, Trimble E, Vasey P, Wagner U;
ANZGOG; AGO-OVAR; NSGO; GOG; EORTC; GEICO; MRC/NCRI; NCIC-CTG; IGCS;
GINECO; NCI-US; SGCTG.
Ann Oncol. 2005;16 Suppl 8:viii30-viii35
2004
New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E,
Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J.
J Natl Cancer Inst. 2004 Mar 17;96(6):487-8.
2003
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the
cyclophosphamide-cisplatin combination in advanced ovarian cancer.
Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote
I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers
P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B,
McGuire W
Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:144-8.
First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus
paclitaxel/carboplatin.
Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Lopez AB, Eisenhauer E, AavallLundquist E, Ridderheim M, Havsteen H, Mirza MR, Scheistroen M, Vrdoljak E.
Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:172-7.
9
PMID: 14656276 [PubMed - indexed for MEDLINE]
Related citations
2002
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent
carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer:
the ICON3 randomised trial.
The International Collaborative Ovarian Neoplasms (ICON) Group.
Lancet 360:505-515, 2002
Attitudes towards clinical research amongst participants and nonparticipants.
Madsen SM, Mirza MR, Holm S, Hilsted KL, Kampmann K, Riis P.
J Intern Med. 2002 Feb;251(2):156-68.
PMID: 11905591 [PubMed - indexed for MEDLINE]
Related citations
2001
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial
ovarian carcinoma.
Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore E, Kaern J,
Verrelst H, Sjovall K, Timmerman D, Vandewalle J, Van Gramberen , Trope CG.
Lancet. 2001 Jan 20;357(9251):176-82.
2000
New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer].
Gynecologic Cancer Intergroup.
Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK,
Friedlander M, Jakobsen A, Vermorken JB.
J Natl Cancer Inst. 2000 Sep 20;92(18):1534-5.
Randomized study on adjuvant chemotherapy in stage I high risk ovarian cancer with
evaluation of DNA-ploidy as prognostic instrument
Tropé C., Kaern J., Hogberg T., Abeler V., Hagen B., Kristensen G., Onsrud M., Pettersen
E., Rosenberg P., Sandvei R., Sunfor K. And Vergote I.
Annals of Oncology 11, 281-288, 2000
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women
with advanced epithelial ovarian cancer: three-year results.
Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote
I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope CG, Nardi M, Kaern J, Tumolo S,
Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B,
Pecorelli S.
J Natl Cancer Inst. 2000 May 3;92(9):699-708.
10
Epithelial ovarian cancer (advanced stage): consensus conference (1998)
Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore , Grenman S,
Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck J, Lund B, McGuire WP, Neijt JP,
Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C,
Thigpen JT, Trope C, Tuxen K, Vergote I, Vermorken JB, Willemse PH.
Gynecol Obstet Fertil. 2000 Jul-Aug;28(7-8):576-83.
1999
Advanced epithelial ovarian cancer: 1998 consensus statements
Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore , Grenman S,
Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck J, Lund B, McGuire WP, Neijt JP,
Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C,
Willemse PH, et al.
Ann Oncol. 1999;10 Suppl 1:87-92
Intergroup collaboration in ovarian cancer: a giant step forward.
Piccart MJ, Stuart GC, Cassidy J, Bertelsen K, Parmar MK, Eisenhauer EA, Kaye B, Trope C,
Swenerton K, Harper P, Vermorken JB.
Ann Oncol. 1999;10 Suppl 1:83-6.
1997
Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies.
Mirza MR, Jakobsen E, Pfeiffer P, Lindebjerg-Clasen B, Bergh J, Rose C.
Acta Oncol. 1997;36(2):171-4.
PMID: 9140434 [PubMed - indexed for MEDLINE]
Related citations
1996
Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter
study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma
stage 3B and 4A
Sundfor K, Trope CG, Hogberg T, Onsrud M, Koern J, Simonsen E, Bertelsen K, Westberg
R.
Cancer. 1996 Jun 1;77(11):2371-8.
1994
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together
11
with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.
Jakobsen P, Sørensen B, Bastholt L, Mirza MR, Gjedde SB, Mouridsen HT, Rose C.
Cancer Chemother Pharmacol. 1994;35(1):45-52.
PMID: 7987976 [PubMed - indexed for MEDLINE]
Related citations
The cardioprotector ADR-529 and high-dose epirubicin given in combination with
cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer.
Sørensen B, Bastholt L, Mirza MR, Gjedde SB, Jakobsen P, Mouridsen HT, Rose C.
Cancer Chemother Pharmacol. 1994;34(5):439-43.
PMID: 8070013 [PubMed - indexed for MEDLINE]
Related citations
1992
The integration of radiotherapy into the primary treatment of non-Hodgkin's lymphoma.
Mirza MR, Brincker H, Specht L.
Crit Rev Oncol Hematol. 1992;12(3):217-29. Review. No abstract available.
PMID: 1497822 [PubMed - indexed for MEDLINE]
Related citations
1991
Anti-estrogen induced synthesis of transforming growth factor-beta in breast cancer patients.
Mirza MR.
Cancer Treat Rev. 1991 Jun;18(2):145-8. Review.
PMID: 1804525 [PubMed - indexed for MEDLINE]
Related citations
MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A
phase II study.
Mirza MR, Brincker H.
Acta Oncol. 1991;30(1):17-21.
PMID: 2009179 [PubMed - indexed for MEDLINE]
Related citations
12
Submitted:
Published abstracts
2008:
G. B. Kristensen, J. Kaern, M. Baekelandt, T. Skeie-Jensen, R. dePont Christensen, E. ÅvallLundqvist, M. Bergdahl, R. Sandvei, T. Hoegberg, S. Grenman
Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian
cancer- a NSGO study (NSGO-OC-0101)
Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings Part I.
Vol 26, No. 15S, (May 20,2008). Abstract #5508
2007:
T. Hogberg, P. Rosenberg, G. Kristensen, CF de Oliviera, R dePont Christensen, B Sorbe, C
Lundgren, H Andersson, T Salmi, NF Reed.
A randomized phase-III study on adjuvant treatment with radiation (RT) 177; chemotherapy (CT)
in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991).
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S
(June 20 Supplement), 2007: 5503. Abstract #5503
2006:
Britta Nordström, Tuula Salmi, Mansoor R Mirza, Vera Abeler and Gunnar Kristensen
Exemestane in advanced and recurrent endometrial carcinoma. A phase II study. J
Clin Oncol 2006;24,18S:266, abstract #5042
2004:
Kristensen GB et al.
First Line Treatment of Ovarian Cancer: Paclitaxel/Epirubicin/Carboplatin (TEC) versus
Paclitaxel/Carboplatin (TC). Report on progression free survival
Proc Am Soc Clin Oncol abst # 5003. 2004.
I. Vergote, G. Kristensen, G. Stuart, J.M. del Campo J. Kærn, M. Baekelandt, A.B Lopez, H.
Hirte, E. Aavall-Lundquist, E. Lorenz, O. Cerar
First line treatment of ovarian/tubal/peritoneal cancer figo stage IIb-IV with paclitaxel/ carboplatin
with or without epirubicin (TEC vs TC).
A gynecologic cancer intergroup study of the NSGO, EORTC-GCG, and NCIC-GCG. Results on
progression free survival.
International Journal of Gynecological Cancer Suppl 1, 2004. Abst#007
2002:
Kristensen G, Vergote IV, Stuart G, Izquerdo Delso M, Mirza M, Aaval- Lundquist E, Lopez
AB, Ridderheim M, Havsteen H, Scheistroen M, Eisenhauer E.
First line treatment of ovarian cancer FIGO stage Ib-IV with paclitaxel/epirubicin/carboplatin
(TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-GCCG-NCIC CTG
Gynecological Cancer Intergroup phase III trial.
13
Proc Am Soc Clin Oncol abst # 805. 2002.
Vergote I, Kristensen G, Stuart G, Aaval-Lundquist E, Kaern J, Eisenhauer E.
First line treatment of ovarian cancer FIGO stage Ib-IV with paclitaxel/epirubicin/carboplatin
(TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-GCCG-NCIC
CTG Gynecological Cancer Intergroup phase III trial.
Int J Gynecol Cancer. 12(5): 521 (abstract # OV007), 2002
Communications:
2010:
Eric Pujade-Lauraine on behalf of all GCIG collaborators
CALYPSO trial. Carboplatin & Pegylated Liposomal Doxorubicin (PLD)versus Carboplatin &
Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer
Oral presentation at 2010 ASCO Annual Meeting
Tim Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan Ledermann, Eric Pujade-Lauraine,
Gunnar Kristensen, Mark Carey, Philip Beale, Andreas Cervantes, Amit Oza on behalf of GCIG
ICON7 collaborators
Results of ICON7: A phase III randomised two-arm Gynaecologic Cancer InterGroup (GCIG) trial of
concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus
chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal
(PPC) or fallopian tube cancer (FTC).
Oral presentation at 2010 ASCO Annual Meeting
Paul Vasey on behalf of all GCIG ICON7 collaborators
Results of ICON7: A phase III randomised two-arm Gynaecologic Cancer InterGroup (GCIG) trial of
concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus
chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal
(PPC) or fallopian tube cancer (FTC).
Oral presentation at 2010 ESMO Meeting
Mark Heywood on behalf of all GCIG ICON7 collaborators.
Results of ICON7: A phase III randomised two-arm Gynaecologic Cancer InterGroup (GCIG) trial of
concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus
chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal
(PPC) or fallopian tube cancer (FTC).
Oral presentation at 2010 ESMO Meeting
2009:
Jørn Herrstedt, Huober, Franck Priou, Stats, NSGO, Kurzeder, Jacob Pfisterer, Stähle, I RayCoquard, Andreas du Bois2 (PI). for the GCIG Intergroup of), NSGO (Scandinavia), AGO-OVAR
(Germany) and GINECO (France ).
A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabinepaclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian
14
cancer (OS): survival of FIGO stage I-IIA patients
Oral presentation at 2009 ASCO Annual Meeting
2008:
G. B. Kristensen, J. Kaern, M. Baekelandt, T. Skeie-Jensen, R. dePont Christensen, E. ÅvallLundqvist, M. Bergdahl, R. Sandvei, T. Hoegberg, S. Grenman
Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian
cancer- a NSGO study (NSGO-OC-0101)
Oral presentation at 2008 ASCO Annual Meeting.
G. Kristensen, J. Kaern, E. Åvall-Lundqvist, R. Christensen, S. Grenmann, M. Bergdahl, R.
Sandvei, M. Baekelandt, T. Skeie-Jensen, M. Kalling, T. Hoegberg
CHEMOTHERAPY VERSUS HORMONAL TREATMENT IN PATIENTS WITH PLATINUM AND
TAXANE RESISTANT OVARIAN CANCER - A NSGO STUDY
IGCS 12.th Biennial Meeting, 2008 Bangkok, Thailand
A. du Bois, G. Kristensen, F. Joly, H.-H. Müller, A. Belau, E. Avall-Lundqvist, B. Weber, L.
Hanker, J. Lindegaard, E. Levy, H.-J. Lück, K. Wollschlaeger,
U. Canzler, W. Schröder, J. Sehouli, J. Huober
RANDOMIZED PHASE-III GCIG STUDY (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102):
GEMCITABINE-PACLITAXEL-CARBOPLATIN (TCG) VS. PACLITAXEL-CARBOPLATIN (TC)
AS FIRST-LINE TREATMENT OF OVARIAN CANCER (OC)
IGCS 12.th Biennial Meeting, 2008 Bangkok, Thailand
2007:
T. Hogberg, P. Rosenberg, G. Kristensen, CF de Oliviera, R dePont Christensen, B Sorbe, C
Lundgren, H Andersson, T Salmi, NF Reed.
A randomized phase-III study on adjuvant treatment with radiation (RT) 177; chemotherapy (CT)
in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991).
Oral presentation at 2007 ASCO Annual Meeting.
GB. Kristensen, I. Vergote, G. Stuart, J.M. del Campo, J. Kærn, M. Baekelandt, A.B. Lopez, H.
Hirte, E. Aavall-Lundqvist, E. Lorenz & O. Cerar
First-line treatment of ovarian/tubal/peritoneal cancer figo stage IIb–IV with paclitaxel/carboplatin
with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO,
EORTC GCG, and NCI-C CTG. Results on overall survival
Poster at ESGO15, Berlin, 2007
B. Nordstrom, M. Mirza, Rene dePont Christensen, H. Oksefjell, G. Kristensen;
Exemestane in advanced and recurrent endometrial carcinoma.
A phase II study by NSGO Poster
at ESGO15, Berlin, 2007
M. Baekelandt, J. Herrstedt, R dePont Christensen, J. Kærn, B. Lund, M. Mirza, T. Skeie Jensen, J.
Mäenpää, E. Lindegaard Madsen, G.B. Kristensen
15
A Nordic Society of Gynecological Oncology (NSGO) multicenter, non-randomized phase II study
of docetaxel and carboplatin as second line chemotherapy in patients with first relapse of
platinum-sensitive epithelial ovarian, peritoneal or fallopian tube cancer
Poster at ESGO15, Berlin, 2007
2006:
Britta Nordström, Tuula Salmi,Mansoor R Mirza, Vera Abeler and Gunnar Kristensen
Exemestane in advanced and recurrent endometrial carcinoma. A
phase II study.
Poster ASCO Atlanta, USA, 2006
2002:
Kristensen G, Vergote IV, Stuart G, Izquerdo Delso M, Mirza M, Aaval- Lundquist E, Lopez AB,
Ridderheim M, Havsteen H, Scheistroen M, Eisenhauer E.
First line treatment of ovarian cancer FIGO stage Ib-IV with paclitaxel/epirubicin/carboplatin
(TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-GCCG-NCIC CTG
Gynecological Cancer Intergroup phase III trial.
Am Soc Clin Oncol 2002
Stuart G, Kristensen G, Vergote IV, Izquerdo Delso M, Mirza M, Aaval- Lundquist E, Lopez AB,
Ridderheim M, Havsteen H, Scheistroen M, Eisenhauer E.
First line treatment of ovarian cancer FIGO stage Ib-IV with paclitaxel/epirubicin/carboplatin
(TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-GCCG-NCIC CTG
Gynecological Cancer Intergroup phase III trial.
Consensus statements/reviews:
1999:
Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore , Grenman S,
Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck J, Lund B, McGuire WP, Neijt
JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa
C, Willemse PH, et al
Advanced epithelial ovarian cancer: 1998 consensus statements.
Ann Oncol. 1999;10 Suppl 1:87-92
Piccart MJ, Stuart GC, Cassidy J, Bertelsen K, Parmar MK, Eisenhauer EA, Kaye B, Trope C,
Swenerton K, Harper P, Vermorken JB.
Intergroup collaboration in ovarian cancer: a giant step forward.
Ann Oncol. 1999;10 Suppl 1:83-6.
16
1993:
Allen DG, Baak J, Belpomme D, Berek JS, Bertelsen K, ten Bokkel Huinink W, van der Burg ME,
Calvert AH, Conte PF, Dauplat J, et al
Advanced epithelial ovarian cancer: 1993 consensus statements.
Ann Oncol. 1993;4 Suppl 4:83-8.
17
`